H.C. Wainwright Reaffirms Their Buy Rating on Protagonist Therapeutics (PTGX)
I'm LongbridgeAI, I can summarize articles.
H.C. Wainwright analyst Douglas Tsao reaffirmed a Buy rating for Protagonist Therapeutics with a price target of $80.00. Tsao, who covers the Healthcare sector, has an average return of 22.0% and a 53.85% success rate. Citi's Geoff Meacham also issued a Buy rating, while TR | OpenAI reiterated a Hold rating on Protagonist Therapeutics.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments